Efficacy and safety of Chinese herbal medicine in the treatment of chronic pruritus: A systematic review and meta-analysis of randomized controlled trials

Wang, Jie; Chen, Yuhang; Yang, Xinwei; Huang, Jian; Xu, Yangsheng; Wei, Wei; Wu, Xin

doi:10.3389/fphar.2022.1029949

Cited by 3 publications

(2 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mahira's study [21] shows that wound infection caused by Enterococcus fecal may become a risk factor for cervical intraepithelial neoplasia. The active ingredients in Kushen gel can quickly enter damaged tissues and increase blood circulation [22]. This feature causes necrotic tissues to separate and exfoliate rapidly, and new epithelium grow rapidly.…”

Section: Discussionmentioning

confidence: 99%

CO2 Cryotherapy Combined with Kushen Gel for the Treatment of Chronic Cervicitis: A Real-World Study

Zhang,

Zhou,

Liu

et al. 2024

Clin. Exp. Obstet. Gynecol.

View full text Add to dashboard Cite

Background: This real-world study aims to investigate clinical efficacy and safety of CO2 cryotherapy combined with Kushen gel for chronic cervicitis. Methods: From June 2021 to December 2021, a total of 363 patients with chronic cervicitis treated in the Center for Diagnosis and Treatment of Cervical Diseases were selected. A total of 208 patients were treated with CO2 cryotherapy combined with Kushen gel, while 155 cases only received cervical CO2 cryotherapy. Results: The total effective rate of combined therapy for chronic cervicitis was 100%, with a higher cure rate than CO2 cryotherapy alone (p = 0.004), and it was significantly correlated with the degree of cervical inflammation (p <0.050). Cure rate increased with decreasing severity of inflammatory response. Conclusions: CO2 cryotherapy combined with Kushen gel for chronic cervicitis has definite clinical efficacy with few adverse reactions and the combined treatment of CO2 cryotherapy with Kushen gel could enhance the therapeutic effect.

show abstract

Section: Discussionmentioning

confidence: 99%

CO2 Cryotherapy Combined with Kushen Gel for the Treatment of Chronic Cervicitis: A Real-World Study

Zhang,

Zhou,

Liu

et al. 2024

Clin. Exp. Obstet. Gynecol.

View full text Add to dashboard Cite

show abstract

“…Thus, the effects of LCI699 on inhibition of cortisol synthesis were recognized and the interest shifted towards developing the drug as a potential treatment for CD. [15][16][17]…”

Section: Historic Perspectives Discovery and Early Drug Developmentmentioning

confidence: 99%

Clinical Utility of Osilodrostat in Cushing’s Disease: Review of Currently Available Literature

Perosevic¹,

Tritos²

2023

DDDT

View full text Add to dashboard Cite

Cushing's disease (CD) is caused by endogenous hypercortisolism as a result of adrenocorticotropin (ACTH) secretion from a pituitary tumor. The condition is associated with multiple comorbidities and increased mortality. First-line therapy for CD is pituitary surgery, performed by an experienced pituitary neurosurgeon. Hypercortisolism may often persist or recur after initial surgery. Patients with persistent or recurrent CD will generally benefit from medical therapy, often administered to patients who underwent radiation therapy to the sella and are awaiting its salutary effects. There are three groups of medications directed against CD, including pituitary-targeted medications that inhibit ACTH secretion from tumorous corticotroph cells, adrenally-directed medications that inhibit adrenal steroidogenesis and a glucocorticoid receptor (GR) antagonist. The focus of this review is osilodrostat, a steroidogenesis inhibitor. Osilodrostat (LCI699) was initially developed to lower serum aldosterone levels and control hypertension. However, it was soon realized that osilodrostat also inhibits 11-beta hydroxylase (CYP11B1), leading to a reduction in serum cortisol levels. The focus of drug development then shifted from treatment of hypertension to treatment of hypercortisolism in CD. In a series of studies (LINC 1 through 4), osilodrostat was shown to be effective in normalizing 24-h urinary free cortisol (UFC) in the majority of treated patients and was approved for patients with CD who have failed surgery or are not surgical candidates. Further study is needed to examine the role of combination therapy as well as long-term outcomes of treated patients. Osilodrostat was shown to have an overall good safety profile. Most common adverse effects include nausea, headache, fatigue, arthralgias, dizziness, prolonged QT c interval, hypokalemia. In females, the drug can cause hirsutism and acne. Osilodrostat is administered twice daily, making it a good choice for patients with difficulty adhering to more complex regimens. Osilodrostat has an important, albeit adjunctive, role in the management of patients with CD.

show abstract

The case for neuregulin-1 as a clinical treatment for stroke

Noll,

Sherafat,

Ford

et al. 2024

Front. Cell. Neurosci.

View full text Add to dashboard Cite

Ischemic stroke is the leading cause of serious long-term disability and the 5th leading cause of death in the United States. Revascularization of the occluded cerebral artery, either by thrombolysis or endovascular thrombectomy, is the only effective, clinically-approved stroke therapy. Several potentially neuroprotective agents, including glutamate antagonists, anti-inflammatory compounds and free radical scavenging agents were shown to be effective neuroprotectants in preclinical animal models of brain ischemia. However, these compounds did not demonstrate efficacy in clinical trials with human patients following stroke. Proposed reasons for the translational failure include an insufficient understanding on the cellular and molecular pathophysiology of ischemic stroke, lack of alignment between preclinical and clinical studies and inappropriate design of clinical trials based on the preclinical findings. Therefore, novel neuroprotective treatments must be developed based on a clearer understanding of the complex spatiotemporal mechanisms of ischemic stroke and with proper clinical trial design based on the preclinical findings from specific animal models of stroke. We and others have demonstrated the clinical potential for neuregulin-1 (NRG-1) in preclinical stroke studies. NRG-1 significantly reduced ischemia-induced neuronal death, neuroinflammation and oxidative stress in rodent stroke models with a therapeutic window of >13 h. Clinically, NRG-1 was shown to be safe in human patients and improved cardiac function in multisite phase II studies for heart failure. This review summarizes previous stroke clinical candidates and provides evidence that NRG-1 represents a novel, safe, neuroprotective strategy that has potential therapeutic value in treating individuals after acute ischemic stroke.

show abstract

Efficacy and safety of Chinese herbal medicine in the treatment of chronic pruritus: A systematic review and meta-analysis of randomized controlled trials

Cited by 3 publications

References 48 publications

CO2 Cryotherapy Combined with Kushen Gel for the Treatment of Chronic Cervicitis: A Real-World Study

CO2 Cryotherapy Combined with Kushen Gel for the Treatment of Chronic Cervicitis: A Real-World Study

Clinical Utility of Osilodrostat in Cushing’s Disease: Review of Currently Available Literature

The case for neuregulin-1 as a clinical treatment for stroke

Contact Info

Product

Resources

About